• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Savas Marc

    1/5/22 6:19:00 PM ET
    $SRAX
    Advertising
    Consumer Discretionary
    Get the next $SRAX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Savas Marc

    (Last) (First) (Middle)
    2629 TOWNSGATE ROAD #215

    (Street)
    WESTLAKE VILLAGE CA 91361

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    SRAX, Inc. [ SRAX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    01/03/2022
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Class A Common Stock Purchase Option(1) $4.35 01/03/2022 A 29,533 01/03/2022 01/03/2029 Class A Common Stock 29,533 $0.00 29,533 D
    Explanation of Responses:
    1. Represents equity grant portion of annual compensation for non-employee director services with such grant valued at $100,000. The options vest quarterly in equal installments on 3/31/22, 6/30/22, 9/30/22, and 12/31/22.
    /s/ Marc Savas 01/05/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SRAX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SRAX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SRAX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Miglino Christopher bought $750 worth of SRAX Common Stock (15,000 units at $0.05), increasing direct ownership by 2% to 902,575 units (SEC Form 4)

      4 - SRAX, Inc. (0001538217) (Issuer)

      12/28/23 5:25:44 PM ET
      $SRAX
      Advertising
      Consumer Discretionary

    $SRAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dawson James initiated coverage on SRAX with a new price target

      Dawson James initiated coverage of SRAX with a rating of Buy and set a new price target of $10.00

      4/19/21 9:31:00 AM ET
      $SRAX
      Advertising
      Consumer Discretionary
    • B. Riley reiterated coverage on SRAX with a new price target

      B. Riley reiterated coverage of SRAX with a rating of Buy and set a new price target of $7.50 from $4.50 previously

      2/12/21 8:22:29 AM ET
      $SRAX
      Advertising
      Consumer Discretionary
    • Ladenburg Thalmann initiated coverage on SRAX with a new price target

      Ladenburg Thalmann initiated coverage of SRAX with a rating of Buy and set a new price target of $7.00

      2/8/21 7:58:16 AM ET
      $SRAX
      Advertising
      Consumer Discretionary

    $SRAX
    SEC Filings

    See more
    • SEC Form 10-Q filed by SRAX Inc.

      10-Q - SRAX, Inc. (0001538217) (Filer)

      4/30/25 6:18:31 AM ET
      $SRAX
      Advertising
      Consumer Discretionary
    • SEC Form 10-Q filed by SRAX Inc.

      10-Q - SRAX, Inc. (0001538217) (Filer)

      3/7/25 6:03:29 AM ET
      $SRAX
      Advertising
      Consumer Discretionary
    • SEC Form 10-K filed by SRAX Inc.

      10-K - SRAX, Inc. (0001538217) (Filer)

      9/20/24 5:29:24 PM ET
      $SRAX
      Advertising
      Consumer Discretionary

    $SRAX
    Financials

    Live finance-specific insights

    See more
    • SRAX Reassures Investors of Business Health Amid Delisting Notice

      Los Angeles, California--(Newsfile Corp. - March 9, 2023) - SRAX, Inc. (NASDAQ:SRAX), a financial technology company that provides data and insights to publicly traded companies through its SaaS platform Sequire, would like to reassure its investors that the company's core business remains strong despite the recent delisting notice from NASDAQ. The delisting was caused by a late filing, and the company is actively working to regain compliance as soon as possible.We are pleased to report that SRAX has added over 25 new customers in the first quarter of 2023, indicating the strength of our business and the value we provide to our clients. We remain confident that this momentum will continue, a

      3/9/23 9:00:00 AM ET
      $SRAX
      Advertising
      Consumer Discretionary
    • Freedom Holding Acquires LD Micro From SRAX, Inc.

      Purchase brings pre-eminent small-cap platform to the Freedom family Freedom U.S. Markets, LLC, a wholly-owned subsidiary of Freedom Holding Corp. (NASDAQ:FRHC), announced today that it has completed the acquisition of LD Micro from SRAX, Inc. (NASDAQ:SRAX). The total consideration of $8.3 million includes $4 million in cash and FRHC common stock valued at $4.3 million. LD Micro offers two premier small-cap conferences annually, the Invitational: June 6-8 (Los Angeles) and the Main Event: October 3-5 (Los Angeles), which hosts over 200 companies and 1,000 investors. For the past 15 years, the LD Micro conferences have showcased the next big names in the small-cap world to investors and i

      3/6/23 8:00:00 AM ET
      $FRHC
      $SRAX
      Investment Bankers/Brokers/Service
      Finance
      Advertising
      Consumer Discretionary
    • SRAX Acquires DNA Holdings Assets

      Los Angeles, California--(Newsfile Corp. - February 6, 2023) - SRAX, Inc. (NASDAQ:SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, has acquired the assets of DNA Holdings, LLC.DNA specializes in helping private technology companies with positioning, marketing, and strategy. The emphasis on private companies provides the expertise for SRAX to accelerate the entrance into the cap table management for private companies. The private cap table management market is anticipated to grow to over $1 Billion by 2030. This market is a natural extension of SRAX's current Sequire Platform that helps public companies m

      2/6/23 8:30:00 AM ET
      $SRAX
      Advertising
      Consumer Discretionary

    $SRAX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • June 7, 2024 - FDA Roundup: June 7, 2024

      For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

      6/7/24 3:46:22 PM ET
      $GERN
      $SRAX
      $SNAP
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Advertising
      Consumer Discretionary
    • March 22, 2024 - FDA Roundup: March 22, 2024

      For Immediate Release: March 22, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued an emergency use authorization for Pemgarda (pemivibart) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and adolescents (12 years of age and older weighing at least 40 kilograms [about 88 pounds]).  Pemgarda is

      3/22/24 5:02:42 PM ET
      $SNAP
      $SRAX
      Computer Software: Programming Data Processing
      Technology
      Advertising
      Consumer Discretionary
    • November 9, 2023 - FDA Approves First Treatment for Patients with Rare Inherited Blood Clotting Disorder

      For Immediate Release: November 09, 2023 Today, the U.S. Food and Drug Administration approved Adzynma, the first recombinant (genetically engineered) protein product indicated for prophylactic (preventive) or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), a rare and life-threatening blood clotting disorder. “The FDA remains

      11/9/23 2:30:20 PM ET
      $SRAX
      $SNAP
      Advertising
      Consumer Discretionary
      Computer Software: Programming Data Processing
      Technology

    $SRAX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SRAX Signs Agreement to Merge with DNA Holdings

      Westlake Village, CA, May 08, 2024 (GLOBE NEWSWIRE) -- SRAX Inc. (OTC:SRAX), a financial technology company that unlocks data and insights for publicly traded companies through its SaaS platform Sequire, announced today it has entered into a definitive merger agreement with DNA Holdings Venture Inc. pursuant to which the shareholders of DNA will become the majority owners of SRAX's outstanding common stock as more fully described below upon the closing of the merger. DNA has been a long term investor in SRAX and currently owns approximately 35% of the company.  DNA is  a Web3 investment company which provides both advisory services and invests in Web3 infrastructure. The company was foun

      5/8/24 8:00:00 AM ET
      $SRAX
      Advertising
      Consumer Discretionary
    • SRAX SELECTS XDEFI AS WEB3 WALLET PARTNER, ENABLING SECURE ACCESS TO DIGITAL ASSETS FOR ACTIVE EQUITY INVESTORS

      Los Angeles, March 05, 2024 (GLOBE NEWSWIRE) -- Los Angeles, [5 March 2024] - SRAX Inc. (OTC:SRAX), a financial technology company that unlocks data and insights for publicly traded companies through its SaaS platform Sequire, today announced it has selected XDEFI as its Web3 wallet partner. XDEFI is a pioneering multichain cryptocurrency wallet. The partnership will enable SRAX's network of active equity investors to access decentralized applications and assets spanning 200+ blockchains, seamlessly and securely. In addition, SRAX clients who download the wallet will be eligible for airdrops in $XDEFI tokens and many future token airdrops.  In 2023, over $5 billion was given away through

      3/5/24 8:30:00 AM ET
      $SRAX
      Advertising
      Consumer Discretionary
    • SRAX SHAREHOLDER LETTER

      Westlake Village, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Dear Shareholders, As I write to you today, I do so with a sense of deep reflection on the year that has passed. It's been a period that tested our resilience. I want to express my sincere regret for the concerns and frustrations you may have experienced as a result of our stock price. Addressing Our Challenges Head-On Our delisting from the NASDAQ market was a moment for serious introspection. Looking back, there were areas where we should have been more proactive, especially as it relates to our accounting team's leadership and the complexities of the accounting for our business.  Bringing in new experts was a turning point for th

      12/18/23 7:00:00 AM ET
      $SRAX
      Advertising
      Consumer Discretionary

    $SRAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by SRAX Inc. (Amendment)

      SC 13G/A - SRAX, Inc. (0001538217) (Subject)

      2/14/24 2:56:29 PM ET
      $SRAX
      Advertising
      Consumer Discretionary
    • SEC Form SC 13G/A filed by SRAX Inc. (Amendment)

      SC 13G/A - SRAX, Inc. (0001538217) (Subject)

      2/13/24 7:42:04 PM ET
      $SRAX
      Advertising
      Consumer Discretionary
    • SEC Form SC 13G/A filed by SRAX Inc. (Amendment)

      SC 13G/A - SRAX, Inc. (0001538217) (Subject)

      2/14/23 3:07:08 PM ET
      $SRAX
      Advertising
      Consumer Discretionary

    $SRAX
    Leadership Updates

    Live Leadership Updates

    See more
    • June 7, 2024 - FDA Roundup: June 7, 2024

      For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

      6/7/24 3:46:22 PM ET
      $GERN
      $SRAX
      $SNAP
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Advertising
      Consumer Discretionary
    • SRAX Announces Appointment of New CFO

      Los Angeles, California--(Newsfile Corp. - March 20, 2023) - SRAX, Inc. (NASDAQ:SRAX), a leading financial technology company, has announced the appointment of Alan Urban as the CFO of SRAX. Mr. Urban has over 30 years of experience in corporate finance and accounting. He has previously served in numerous senior management positions, most notably as Chief Financial Officer for ten years at Research Solutions, a provider of SaaS solutions for life science organizations. Mr. Urban also serves on the Board of Directors of GT Biopharma."We are excited to have Alan step into this very important role at SRAX. We believe his 30 years of expertise will be instrumental in getting our accounting t

      3/20/23 9:00:00 AM ET
      $SRAX
      Advertising
      Consumer Discretionary
    • ICOA Inc. Appoints SRAX to Enhance Investor Communications

      LAS VEGAS, NEVADA , April 14, 2022 (GLOBE NEWSWIRE) -- Publicly traded Nevada blockchain, decentralized finance (DeFi), and cryptocurrency-focused investment company ICOA Inc. (OTC:ICOA) announced this week that they have entered a $500,000 deal with SRAX (NASDAQ:SRAX) to maximize and accelerate its communications for interested investors, shareholders, and supporters. Through SRAX, a publicly traded company offering premier operating system tools for publicly traded companies, ICOA will have the ability to further reach its community through sophisticated solutions to assist it in maintaining, communicating, and expanding its shareholder base. With Sequire, a product of SRAX, IC

      4/14/22 9:42:39 AM ET
      $SRAX
      Advertising
      Consumer Discretionary

    $SRAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Miglino Christopher bought $750 worth of SRAX Common Stock (15,000 units at $0.05), increasing direct ownership by 2% to 902,575 units (SEC Form 4)

      4 - SRAX, Inc. (0001538217) (Issuer)

      12/28/23 5:25:44 PM ET
      $SRAX
      Advertising
      Consumer Discretionary
    • SEC Form 4 filed by Urban Alan Louis

      4 - SRAX, Inc. (0001538217) (Issuer)

      3/22/23 2:57:48 PM ET
      $SRAX
      Advertising
      Consumer Discretionary
    • SEC Form 3 filed by new insider Urban Alan Louis

      3 - SRAX, Inc. (0001538217) (Issuer)

      3/22/23 2:56:42 PM ET
      $SRAX
      Advertising
      Consumer Discretionary